MDT

101.86

+2.58%↑

139.37

+1.08%↑

VEEV

224.64

+2.55%↑

HQY

87.09

+3.13%↑

NEOG

9.94

+4.3%↑

MDT

101.86

+2.58%↑

139.37

+1.08%↑

VEEV

224.64

+2.55%↑

HQY

87.09

+3.13%↑

NEOG

9.94

+4.3%↑

MDT

101.86

+2.58%↑

139.37

+1.08%↑

VEEV

224.64

+2.55%↑

HQY

87.09

+3.13%↑

NEOG

9.94

+4.3%↑

MDT

101.86

+2.58%↑

139.37

+1.08%↑

VEEV

224.64

+2.55%↑

HQY

87.09

+3.13%↑

NEOG

9.94

+4.3%↑

MDT

101.86

+2.58%↑

139.37

+1.08%↑

VEEV

224.64

+2.55%↑

HQY

87.09

+3.13%↑

NEOG

9.94

+4.3%↑

Strona główna・Stock List・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Open

SectorHealthcare

12.76 0.63

Buy Sell

Overview

Share price change

24h

Current

Min

12.18

Max

12.95

Key metrics
By Trading Economics
Income	-445K -19M
Sales	-3.2M 15M
Profit margin	-123.636
Employees	120
EBITDA	-883K -16M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+48.12% upside

Dividends
By Dow Jones
Next Earnings	6 lut 2026

Market Stats
By TradingEconomics
Market Cap	-6.1M 364M
Previous open	12.13
Previous close	12.76

News Sentiment

By Acuity

50%

177 / 360 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

5.04 / 5.44 Support & Resistance

ENANTA PHARMACEUTICALS INC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 sty 2026, 23:49 UTC

Major Market Movers

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 sty 2026, 21:12 UTC

Major Market Movers

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 sty 2026, 21:00 UTC

Acquisitions, Mergers, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 sty 2026, 20:29 UTC

Major Market Movers

Chip Makers Gain After Trump Calls Off European Tariffs

21 sty 2026, 20:04 UTC

Major Market Movers

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 sty 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 sty 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 sty 2026, 22:39 UTC

Earnings

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 sty 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 sty 2026, 21:35 UTC

Acquisitions, Mergers, Takeovers

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 sty 2026, 21:19 UTC

Earnings

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 sty 2026, 20:45 UTC

Acquisitions, Mergers, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 sty 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 sty 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 sty 2026, 20:27 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 sty 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 sty 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21 sty 2026, 20:26 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 sty 2026, 20:23 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 sty 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 sty 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Group Agrees to Buy Allfunds

21 sty 2026, 20:08 UTC

Earnings

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 sty 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 sty 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 sty 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21 sty 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21 sty 2026, 19:24 UTC

Earnings

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 sty 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 sty 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer Comparison

Price change

ENANTA PHARMACEUTICALS INC Forecast

Price Target

By TipRanks

48.12% upside

12 Months Forecast

Average 18.5 USD 48.12%

High 20 USD

Low 17 USD

Based on 2 Wall Street analysts offering 12 month price targets forENANTA PHARMACEUTICALS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to ENANTA PHARMACEUTICALS INC - Dist in the past 3 months.

Technical Score

By Trading Central

5.04 / 5.44Support & Resistance

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

177 / 360 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.